EGFR mutation testing is crucial for NSCLC treatment, but global disparities exist in access to comprehensive molecular diagnostics. Third-generation inhibitors and combination regimens improve ...
MediBeacon ® Transdermal GFR System (TGFR) is a first-in-kind product for point of care assessment of kidney function in patients with normal or ...
Pinetree Therapeutics will help AstraZeneca plant some trees in its pipeline with a new pact to develop a preclinical EGFR degrader worth $45 million upfront for the small biotech. AstraZeneca is also ...
The FDA has granted accelerated approval to sunvozertinib (Zegfrovy, Dizal Pharmaceutical) for locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor ( ...
Please provide your email address to receive an email when new articles are posted on . Risk for developing kidney failure outpaced death for adults with diabetes and low eGFR. Lower eGFR, older age, ...
First-line aumolertinib plus platinum-pemetrexed chemotherapy significantly improved progression-free survival (PFS) compared with aumolertinib alone in certain patients with epidermal growth factor ...
A retrospective analysis of 1,804 patients with NSCLC undergoing next-generation sequencing (NGS) in 2019-2024 at University Hospital Würzburg (single-center cohort, including 15 patients with ...
First-line osimertinib (Tagrisso) plus chemotherapy significantly improved survival versus osimertinib monotherapy in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC). Among a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback